Position in CAI
as of Jun 30, 2026
· filed Aug 5, 2026
Position Value
$542,494
+$356,149 QoQ
Shares Held
30,443
+192.1% QoQ
Ownership
0.011%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#116
of 246 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 59%
Shared 0%
None 41%
Common Shares in CAI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026EMERALD ADVISERS, LLC holds $600,984,884 across 23 Biotechnology names. CAI ranks #19 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TVTX |
Travere Therapeutics, Inc.
|
1,600,886 | $90,946,333 | |
| 2 | CORT |
Corcept Therapeutics Inc
|
748,325 | $65,066,858 | |
| 3 | COGT |
Cogent Biosciences, Inc.
|
1,603,319 | $62,048,445 | |
| 4 | MIRM |
Mirum Pharmaceuticals, Inc.
|
468,295 | $54,823,295 | |
| 5 | SYRE |
Spyre Therapeutics, Inc.
|
567,430 | $50,376,435 | |
| 6 | CYTK |
Cytokinetics Inc
|
457,956 | $39,013,271 | |
| 7 | MANE |
Veradermics, Inc
|
288,370 | $35,452,207 | |
| 8 | PVLA |
Palvella Therapeutics, Inc.
|
229,486 | $35,070,050 |
All Filings in CAI
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $542,494 | 30,443 | Shares | Sole | 2026-08-05 | |
| 2026-03-31 | $186,345 | 10,422 | Shares | Sole | 2026-05-04 | |
| No filing history on record for this holder in this stock. | ||||||